DRUGphase2small molecule
nmd-670
Mechanism
First-in-class ClC-1 chloride channel inhibitor. Partial block stabilizes muscle membrane charge → potentiates neuromuscular transmission. Originally validated in myasthenia gravis Phase 2.
Related claims (0)
No claims matched “nmd-670” in free-text search.
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.